Company news

Kura Oncology, Inc. news in 2023

Kura Oncology, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

December 7, 2023

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

November 27, 2023

Kura Oncology Reports Third Quarter 2023 Financial Results

November 1, 2023

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

November 1, 2023

Kura Oncology to Participate in Three Upcoming Investor Conferences

October 29, 2023

Kura Oncology to Report Third Quarter 2023 Financial Results

October 25, 2023

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

October 18, 2023

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

October 16, 2023

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 3, 2023

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

September 27, 2023

Kura Oncology to Participate in Cantor Global Healthcare Conference 2023

September 18, 2023

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

August 13, 2023

Kura Oncology Reports Second Quarter 2023 Financial Results

August 2, 2023

Kura Oncology to Report Second Quarter 2023 Financial Results

July 26, 2023

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

June 13, 2023

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

June 12, 2023

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

June 10, 2023

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

May 29, 2023

Kura Oncology to Participate in Two Upcoming Investor Conferences

May 22, 2023

Kura Oncology Reports First Quarter 2023 Financial Results

May 9, 2023

Kura Oncology to Participate in JMP Securities Life Sciences Conference

May 8, 2023

Kura Oncology to Report First Quarter 2023 Financial Results

May 2, 2023

Kura Oncology to Participate in Stifel Targeted Oncology Days

April 17, 2023

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

April 16, 2023

Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting

March 13, 2023

Kura Oncology to Participate in Upcoming Investor Conferences

February 28, 2023

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

February 15, 2023

Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

February 8, 2023

Kura Oncology to Participate in SVB Securities Global Biopharma Conference

February 6, 2023

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor

January 23, 2023

Calls in 2023

Decks in 2023